AM 1-receptor-dependent protection by intermedin of human vascular and cardiac non-vascular cells from ischaemia-reperfusion injury

Journal of Physiology

Volumn 590, Issue 5, 2012, Pages 1181-1197

  Bell, David ^a   Campbell, Malcolm ^a   Ferguson, Matthew ^a   Sayers, Leah ^a   Donaghy, Liz ^a   O'Regan, Anna ^a   Jewhurst, Victoria ^a   Harbinson, Mark ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENOMEDULLIN; ADRENOMEDULLIN RECEPTOR; CALCITONIN RECEPTOR LIKE RECEPTOR; INTERMEDIN; MESSENGER RNA; RECEPTOR ACTIVITY MODIFYING PROTEIN 1; RECEPTOR ACTIVITY MODIFYING PROTEIN 2; RECEPTOR ACTIVITY MODIFYING PROTEIN 3; SMALL INTERFERING RNA;

ADRENOMEDULLIN GENE; ADULT; ARTERY ENDOTHELIUM; ARTICLE; CELL DISRUPTION; CELL VIABILITY; CELLULAR DISTRIBUTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOSKELETON; DRUG EFFECT; DRUG MECHANISM; FIBROBLAST CULTURE; GENE; GENE EXPRESSION REGULATION; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; HUMAN CELL; INTERMEDIN GENE; MICROVASCULAR ENDOTHELIAL CELL; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN CARBONYLATION; PROTEIN EXPRESSION; REPERFUSION INJURY; SMOOTH MUSCLE FIBER;

ADULT; AORTA; CALCITONIN GENE-RELATED PEPTIDE; CELLS, CULTURED; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; FIBROBLASTS; HUMANS; MYOCARDIUM; MYOCYTES, SMOOTH MUSCLE; PEPTIDE HORMONES; RECEPTOR ACTIVITY-MODIFYING PROTEINS; RECEPTORS, ADRENOMEDULLIN; REPERFUSION INJURY; RNA, MESSENGER; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 84857681342     PISSN: 00223751     EISSN: 14697793     Source Type: Journal    
DOI: 10.1113/jphysiol.2011.221895     Document Type: Article

References (52)

1. Albertin G, Sorato E, Oselladore B, Mascarin A, Tortorella C & Guidolin D (2010). Involvement of vascular endothelial growth factor signaling in CLR/RAMP1 and CLR/RAMP2-mediated pro-angiogenic effect of intermedin on human vascular endothelial cells. Int J Mol Med 26, 289-294.
2. Bell D & McDermott BJ (2008). Intermedin (adrenomedullin-2): a novel counter-regulatory peptide in the cardiovascular and renal systems. Br J Pharmacol 153(Suppl 1), S247-S262.
3. Bell D, Zhao Y, McCoy FP, Devine A & McDermott BJ (2008). Expression of the counter-regulatory peptide intermedin is augmented in the presence of oxidative stress in hypertrophied cardiomyocytes. Cell Physiol Biochem 21, 409-420.
4. Bell D, Zhao Y, McCoy FP, Devine AB & McDermott BJ (2007). Differential effects of an anti-oxidant intervention on cardiomyocyte expression of adrenomedullin and intermedin and their receptor components in chronic nitric oxide deficiency. Cell Physiol Biochem 20, 269-282.
5. Cai H (2005). Hydrogen peroxide regulation of endothelial function: origins, mechanisms, and consequences. Cardiovasc Res 68, 26-36.
6. Cai Y, Xu MJ, Teng X, Zhou YB, Chen L, Zhu Y, Wang X, Tang CS & Qi YF (2010). Intermedin inhibits vascular calcification by increasing the level of matrix γ-carboxyglutamic acid protein. Cardiovasc Res 85, 864-873.
7. Campbell M, Anderson P & Trimble ER (2008). Glucose lowers the threshold for human aortic vascular smooth muscle cell migration: inhibition by protein phosphatase-2A. Diabetologia 51, 1068-1080.
8. Chen L, Kis B, Hashimoto H, Busija DW, Takei Y, Yamashita H & Ueta Y (2006). Adrenomedullin 2 protects rat cerebral endothelial cells from oxidative damage in vitro. Brain Res 1086, 42-49.
9. Dobrina A & Rossi F (1983). Metabolic properties of freshly isolated bovine endothelial cells. Biochim Biophys Acta 762, 295-301.
10. Dong F, Taylor MM, Samson WK & Ren J (2006). Intermedin (adrenomedullin-2) enhances cardiac contractile function via a protein kinase C- and protein kinase A-dependent pathway in murine ventricular myocytes. J Appl Physiol 101, 778-784.
11. Frayon S, Cueille C, Gnidehou S, Vernejoul de MC & Garel JM (2000). Dexamethasone increases RAMP1 and CRLR mRNA expressions in human vascular smooth muscle cells. Biochem Biophys Res Commun 270, 1063-1067.
12. Fujisawa Y, Nagai Y, Miyatake A, Miura K, Nishiyama A, Kimura S & Abe Y (2007). Effects of adrenomedullin 2 on regional hemodynamics in conscious rats. Eur J Pharmacol 558, 128-132.
13. Gupta S, Mehrotra S, Villalon CM, Garrelds IM, Vries de R, Kats van JP, Sharma HS, Saxena PR & Maassenvandenbrink A (2006). Characterisation of CGRP receptors in human and porcine isolated coronary arteries: evidence for CGRP receptor heterogeneity. Eur J Pharmacol 530, 107-116.
14. Hagiwara M, Bledsoe G, Yang ZR, Smith RS Jr, Chao L & Chao J (2008). Intermedin ameliorates vascular and renal injury by inhibition of oxidative stress. Am J Physiol Renal Physiol 295, F1735-F1743.
15. Hagner S, Haberberger R, Hay DL, Facer P, Reiners K, Voigt K & McGregor GP (2003). Immunohistochemical detection of the calcitonin receptor-like receptor protein in the microvasculature of rat endothelium. Eur J Pharmacol 481, 147-151.
16. Hagner S, Stahl U, Knoblauch B, McGregor GP & Lang RE (2002). Calcitonin receptor-like receptor: identification and distribution in human peripheral tissues. Cell Tissue Res 310, 41-50.
17. Harikumar KG, Simms J, Christopoulos G, Sexton PM & Miller LJ (2009). Molecular basis of association of receptor activity-modifying protein 3 with the family B G protein-coupled secretin receptor. Biochemistry 48, 11773-11785.
18. Hasbak P, Saetrum OO, Eskesen K, Schifter S, Arendrup H, Longmore J & Edvinsson L (2003). Investigation of CGRP receptors and peptide pharmacology in human coronary arteries. Characterization with a nonpeptide antagonist. J Pharmacol Exp Ther 304, 326-333.
19. Hirose T, Totsune K, Mori N, Morimoto R, Hashimoto M, Nakashige Y, Metoki H, Asayama K, Kikuya M, Ohkubo T, Hashimoto J, Sasano H, Kohzuki M, Takahashi K & Imai Y (2008). Increased expression of adrenomedullin 2/intermedin in rat hearts with congestive heart failure. Eur J Heart Fail 10, 840-849.
20. Jansen-Olesen I, Jorgensen L, Engel U & Edvinsson L (2003). In-depth characterization of CGRP receptors in human intracranial arteries. Eur J Pharmacol 481, 207-216.
21. Jia YX, Yang JH, Pan CS, Geng B, Zhang J, Xiao Y, Zhao J, Gerns H, Yang J, Chang JK, Wen JK, Tang CS & Qi YF (2006). Intermedin1-53 protects the heart against isoproterenol-induced ischemic injury in rats. Eur J Pharmacol 549, 117-123.
22. Jolly L, March JE, Kemp PA, Bennett T & Gardiner SM (2009). Mechanisms involved in the regional haemodynamic effects of intermedin (adrenomedullin 2) compared with adrenomedullin in conscious rats. Br J Pharmacol 157, 1502-1513.
23. Kamitani S, Asakawa M, Shimekake Y, Kuwasako K, Nakahara K & Sakata T (1999). The RAMP2/CRLR complex is a functional adrenomedullin receptor in human endothelial and vascular smooth muscle cells. FEBS Lett 448, 111-114.
24. Kindt F, Wiegand S, Loser C, Nilles M, Niemeier V, Hsu SY, Steinhoff M, Kummer W, Gieler U & Haberberger RV (2007). Intermedin: a skin peptide that is downregulated in atopic dermatitis. J Invest Dermatol 127, 605-613.
25. Mahadevan VS, Campbell M, McKeown PP & Bayraktutan U (2006). Internal mammary artery smooth muscle cells resist migration and possess high antioxidant capacity. Cardiovasc Res 72, 60-68.
26. McDermott BJ, McWilliams S, Smyth K, Kelso EJ, Spiers JP, Zhao Y, Bell D & Mirakhur RK (2007). Protection of cardiomyocyte function by propofol during simulated ischemia is associated with a direct action to reduce pro-oxidant activity. J Mol Cell Cardiol 42, 600-608.
27. Morimoto R, Satoh F, Murakami O, Totsune K, Suzuki T, Sasano H, Ito S & Takahashi K (2007). Expression of adrenomedullin2/intermedin in human brain, heart, and kidney. Peptides 28, 1095-1103.
28. Nagoshi Y, Kuwasako K, Cao YN, Imamura T, Kitamura K & Eto T (2004). Tumor necrosis factor-α downregulates adrenomedullin receptors in human coronary artery smooth muscle cells. Peptides 25, 1115-1121.
29. Nikitenko LL, Blucher N, Fox SB, Bicknell R, Smith DM & Rees MC (2006). Adrenomedullin and CGRP interact with endogenous calcitonin-receptor-like receptor in endothelial cells and induce its desensitisation by different mechanisms. J Cell Sci 119, 910-922.
30. Nishikimi T & Matsuoka H (2005). Cardiac adrenomedullin: its role in cardiac hypertrophy and heart failure. Curr Med Chem Cardiovasc Hematol Agents 3, 231-242.
31. Oliver KR, Wainwright A, Edvinsson L, Pickard JD & Hill RG (2002). Immunohistochemical localization of calcitonin receptor-like receptor and receptor activity-modifying proteins in the human cerebral vasculature. J Cereb Blood Flow Metab 22, 620-629.
32. Owji AA, Chabot JG, Dumont Y & Quirion R (2008). Adrenomedullin-2/intermedin induces cAMP accumulation in dissociated rat spinal cord cells: evidence for the existence of a distinct class of sites of action. J Mol Neurosci 35, 355-361.
33. Pan CS, Yang JH, Cai DY, Zhao J, Gerns H, Yang J, Chang JK, Tang CS & Qi YF (2005). Cardiovascular effects of newly discovered peptide intermedin/adrenomedullin 2. Peptides 26, 1640-1646.
34. Pearson LJ, Yandle TG, Nicholls MG & Evans JJ (2009). Intermedin (adrenomedullin-2): a potential protective role in human aortic endothelial cells. Cell Physiol Biochem 23, 97-108.
35. Roh J, Chang CL, Bhalla A, Klein C & Hsu SY (2004). Intermedin is a calcitonin/calcitonin gene-related peptide family peptide acting through the calcitonin receptor-like receptor/receptor activity-modifying protein receptor complexes. J Biol Chem 279, 7264-7274.
36. Saetrum OO, Hasbak P, Vries de R, Saxena PR & Edvinsson L (2000). Positive inotropy mediated via CGRP receptors in isolated human myocardial trabeculae. Eur J Pharmacol 397, 373-382.
37. Sams A, Knyihar-Csillik E, Engberg J, Szok D, Tajti J, Bodi I, Edvinsson L, Vecsei L & Jansen-Olesen I (2000). CGRP and adrenomedullin receptor populations in human cerebral arteries: in vitro pharmacological and molecular investigations in different artery sizes. Eur J Pharmacol 408, 183-193.
38. Serrano MC, Pagani R, Manzano M, Comas JV & Portoles MT (2006). Mitochondrial membrane potential and reactive oxygen species content of endothelial and smooth muscle cells cultured on poly(epsilon-caprolactone) films. Biomaterials 27, 4706-4714.
39. Sexton PM, Morfis M, Tilakaratne N, Hay DL, Udawela M, Christopoulos G & Christopoulos A (2006). Complexing receptor pharmacology: modulation of family B G protein-coupled receptor function by RAMPs. Ann N Y Acad Sci 1070, 90-104.
40. Smith RS Jr, Gao L, Bledsoe G, Chao L & Chao J (2009). Intermedin is a new angiogenic growth factor. Am J Physiol Heart Circ Physiol 297, H1040-H1047.
41. Song JQ, Teng X, Cai Y, Tang CS & Qi YF (2009). Activation of Akt/GSK-3β signaling pathway is involved in intermedin(1-53) protection against myocardial apoptosis induced by ischemia/reperfusion. Apoptosis 14, 1299-1307.
42. Takei Y, Inoue K, Ogoshi M, Kawahara T, Bannai H & Miyano S (2004). Identification of novel adrenomedullin in mammals: a potent cardiovascular and renal regulator. FEBS Lett 556, 53-58.
43. Taylor MM, Bagley SL & Samson WK (2006). Intermedin/adrenomedullin-2 inhibits growth hormone release from cultured, primary anterior pituitary cells. Endocrinology 147, 859-864.
44. Townsend PA, Cutress RI, Carroll CJ, Lawrence KM, Scarabelli TM, Packham G, Stephanou A & Latchman DS (2004). BAG-1 proteins protect cardiac myocytes from simulated ischemia/reperfusion-induced apoptosis via an alternate mechanism of cell survival independent of the proteasome. J Biol Chem 279, 20723-20728.
45. Udawela M, Hay DL & Sexton PM (2004). The receptor activity modifying protein family of G protein coupled receptor accessory proteins. Semin Cell Dev Biol 15, 299-308.
46. Hoek Vanden T, Becker LB, Shao ZH, Li CQ & Schumacker PT (2000). Preconditioning in cardiomyocytes protects by attenuating oxidant stress at reperfusion. Circ Res 86, 541-548.
47. Yang JH, Cai Y, Duan XH, Ma CG, Wang X, Tang CS & Qi YF (2009). Intermedin 1-53 inhibits rat cardiac fibroblast activation induced by angiotensin II. Regul Pept 158, 19-25.
48. Yang JH, Jia YX, Pan CS, Zhao J, Ouyang M, Yang J, Chang JK, Tang CS & Qi YF (2005). Effects of intermedin(1-53) on cardiac function and ischemia/reperfusion injury in isolated rat hearts. Biochem Biophys Res Commun 327, 713-719.
49. Yang JH, Ma CG, Cai Y, Pan CS, Zhao J, Tang CS & Qi YF (2010). Effect of intermedin1-53 on angiotensin II-induced hypertrophy in neonatal rat ventricular myocytes. J Cardiovasc Pharmacol 56, 45-52.
50. Zeng Q, Yuan Y, Wang X, Wu HM, Fan L, Qi YF, Tang CS, Cai Y & Pan CS (2009). Upregulated expression of intermedin and its receptor in the myocardium and aorta in spontaneously hypertensive rats. Peptides 30, 391-399.
51. Zhang HY, Jiang W, Liu JY, Li Y, Chen CL, Xin HB & Huang DJ (2009). Intermedin is upregulated and has protective roles in a mouse ischemia/reperfusion model. Hypertens Res 32, 861-868.
52. Zhao Y, Bell D, Smith LR, Zhao L, Devine AB, McHenry EM, Nicholls DP & McDermott BJ (2006). Differential expression of components of the cardiomyocyte adrenomedullin/intermedin receptor system following blood pressure reduction in nitric oxide-deficient hypertension. J Pharmacol Exp Ther 316, 1269-1281.